Eliminating Systematic Underdiagnosis in Prostate Cancer

White Paper: The Clinical and Economic Imperative of Enhanced Tissue Preservation via BxBoard

Executive Summary

Prostate biopsy remains the gold standard for diagnosis, yet traditional collection methods frequently compromise tissue integrity. The transition from multiple formalin bottles to the BxBoard, a 6-lane collection device utilizing a formalin-soaked sponge, has revealed a critical reality: traditional methods have led to the systematic underdiagnosis of high-grade prostate cancer. By preserving tissue length and orientation, the BxBoard enables a significant upgrading trend, ensuring patients receive treatment aligned with the true severity of their disease while mitigating the catastrophic costs associated with late-stage progression.

The Problem: Fragmented Data, Fragmented Care

Standard biopsy collection involves dropping delicate cores into individual formalin bottles. This process often leads to:

• Physical Distortion: Tissue fragmentation, curling, poor orientation, and linear variability of the specimen in the block.
• Diagnostic Noise: Diminished ability for pathologists to accurately assess primary Gleason patterns.
• Artificial Downgrading: Inaccurate “under-calls” of aggressive tumors due to a lack of visual clarity.

The Evidence: The Upward Shift in Severity

Data comparing results following BxBoard implementation demonstrates a significant shift toward higher diagnostic severity. By preserving full tissue length, the diagnostic landscape has been redefined:

The decrease in Grade Group 1 and 2 suggests these cases were accurately reclassified into higher, more aggressive groups due to superior tissue visualization.

The “Why”: The Mechanics of Superior Fixation

Research suggests three primary drivers for this diagnostic upgrading:

1. Full Tissue Length: Maintaining the entire core allows pathologists to see transitions between patterns (e.g., from 3 to 4) that are missed if the tissue breaks at the point of the aggressive pattern.
2. Elimination of Fragmentation: Intact samples reveal the true percentage of high-grade patterns, preventing “under-calls.”
3. Optimal Fixation: The formalin-soaked sponge ensures uniform, rapid fixation compared to a core floating randomly in a bottle, preserving cellular morphology.

The Economic Case: The ROI of Precision

The BxBoard fundamentally alters the financial trajectory of prostate cancer management in the U.S. by addressing three key areas:

1. Avoiding “Metastatic Cost Escalation”

The most significant cost driver is the progression of underdiagnosed cancer.

• The Progression Tax: Annual per-patient costs for metastatic cancer range from $31,4271 to $55,949.²
• The mCRPC Surge: If disease reaches the metastatic castration-resistant stage, annual costs skyrocket to between $111,060 and $182,156.³
• BxBoard Value: Identifying high-grade cases at the initial biopsy allows for curative-intent treatment, potentially bypassing six-figure expenditures for advanced disease.

2. Reducing the “Surgical Margin Tax”

Accurate pre-operative grading is essential for the 60,000+ radical prostatectomies performed annually.

• Positive Surgical Margins (PSM): Fragmented data increases PSM risk, carrying an attributable cost of $17,356 per case.⁴
• Adjuvant Radiation Costs: Misdiagnosis often necessitates secondary interventions. A full course of adjuvant radiation therapy in the U.S. typically costs between $4,500 and $50,000.⁵
• The BxBoard Value: The device’s ability to preserve full tissue length and orientation allows for a more accurate surgical road map, directly reducing the likelihood of costly secondary treatments.

3. Mitigating Patient Financial Toxicity

• Triple Expenditures: U.S. men with a history of prostate cancer incur nearly triple the annual healthcare costs of those without.⁶
• Out-of-Pocket Hardship: Over 50% of advanced prostate cancer patients experience significant financial toxicity.⁷
• BxBoard Value: Accurate initial detection reduces the long-term out-of-pocket burden through more efficient treatment cycles.

Strategic Implications

• • For Urologists: A more aggressive (and accurate) diagnosis impacts the treatment algorithm. Patients once categorized for “Active Surveillance” may now be correctly identified for surgery or radiation, reducing the risk of missed curative opportunities.
  • For Pharma: Accurate grading ensures cleaner data for clinical trials. BxBoard ensures patients enrolled in high-grade trials actually possess the required pathology, maximizing efficacy and safety profiles.

• For Molecular Testing: The BxBoard reduces cancelled tests by 2.1x by reducing QNS and RNA degradation issues.⁸

• Operational Efficiency: Replacing six bottles with one 6-lane device reduces supply chain complexity, biohazard waste, and labor time for both urology and pathology staff.

Conclusion

The BxBoard is more than a collection tool; it is a clinical insurance policy. By eliminating the systematic underdiagnosis inherent in traditional bottles, healthcare systems can ensure that aggressive treatment plans are reserved for the aggressive cancers we are finally seeing clearly. Utilizing the BxBoard allows providers to bypass the catastrophic costs of late-stage progression and surgical failure.

References

1. Olsen TA, Filson CP, Richards TB, Ekwueme DU, Howard DH. The Cost of Metastatic Prostate Cancer in the United States. Urol Pract. 2023;10(1):41-47. doi:10.1097/UPJ.0000000000000363
2. Horný M, Yabroff KR, Filson CP, et al. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance. Cancer. 2023;129(20):3252-3262. doi:10.1002/cncr.34905
3. Kaye DR, Khilfeh I, Muser E, et al. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. J Manag Care Spec Pharm. 2024;30(7):684-697. doi:10.18553/jmcp.2024.30.7.684
4. Martini A, Marqueen KE, Falagario UG, et al. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. JAMA Netw Open. 2020;3(3):e201913. Published 2020 Mar 2. doi:10.1001/jamanetworkopen.2020.1913
5. GoodRx. Radiation therapy cost guide: how much can you expect to pay? Updated December 17, 2024. Accessed April 7, 2026. https://www.goodrx.com/health-topic/finance/radiation-therapy-cost
6. American Cancer Society Cancer Action Network. The Costs of Prostate Cancer. American Cancer Society Cancer Action Network; 2023. Accessed April 7, 2026. https://www.fightcancer.org/sites/default/files/national_documents/the-costs-of-prostate-cancer.pdf
7. Joyce DD, Boehmer KR, Kamath CC, et al. Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective Interventions. Urol Pract. 2024;11(4):640-652. doi:10.1097/UPJ.0000000000000589
8. Lumea Digital. Eliminating Systematic Underdiagnosis in Prostate Cancer: The Impact of Enhanced Tissue Preservation via BxBoard. Lumea Research & Publications; 2023. Accessed April 7, 2026. https://lumeadigital.com/improving-specimen-integrity-with-the-bxboard/

Bianca Collings Chief Marketing Officer

Bianca Collings is Chief Marketing Officer at Lumea, where she leads GTM strategy, brand, product marketing, and SEO for the U.S. leader in primary clinical digital pathology. With more than four years at the forefront of digital pathology marketing and over a decade of executive marketing leadership, she brings deep expertise in how labs, pathologists, and clinicians evaluate and adopt diagnostic technology. Bianca holds an MBA in Marketing from Utah Valley University, where she also serves on the Marketing Board of Advisors and has taught content marketing strategy as an adjunct professor.

See Full Bio